251 related articles for article (PubMed ID: 30586259)
1. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
Tanghetti E; Lebwohl M; Stein Gold L
J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
[TBL] [Abstract][Full Text] [Related]
2. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
Tanghetti E; Lebwohl M; Stein Gold L
J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586260
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
4. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
[TBL] [Abstract][Full Text] [Related]
5. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
6. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
8. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of topical tazarotene: a review.
Talpur R; Cox K; Duvic M
Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
[TBL] [Abstract][Full Text] [Related]
10. Tazarotene gel: efficacy and safety in plaque psoriasis.
Weinstein GD
J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554
[TBL] [Abstract][Full Text] [Related]
11. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815
[TBL] [Abstract][Full Text] [Related]
12. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
Ramachandran V; Bertus B; Bashyam AM; Feldman SR
Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
[No Abstract] [Full Text] [Related]
13. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis.
Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA
Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
[TBL] [Abstract][Full Text] [Related]
16. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
Lebwohl MG; Breneman DL; Goffe BS; Grossman JR; Ling MR; Milbauer J; Pincus SH; Sibbald RG; Swinyer LJ; Weinstein GD; Lew-Kaya DA; Lue JC; Gibson JR; Sefton J
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 1):590-6. PubMed ID: 9777766
[TBL] [Abstract][Full Text] [Related]
17. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
[TBL] [Abstract][Full Text] [Related]
19. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
Angelo JS; Kar BR; Thomas J
Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
